Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donaperminogene seltoplasmid
- Development stage
- Unknown
- Lead developer
- Helixmith
- Modality
- Gene Therapies
- Administration
- Intramuscular
01
Overview
Donaperminogene seltoplasmid (NL003, VM202) is a non-viral plasmid DNA-based gene therapy designed to express two isoforms of human hepatocyte growth factor (HGF): HGF723 and HGF728. Developed by Helixmith (formerly ViroMed) and licensed to Northland Biotech in China, the therapy is administered via local intramuscular injection. Once inside skeletal muscle cells, the plasmid drives the continuous secretion of active HGF, which binds to the c-Met receptor to promote therapeutic angiogenesis, neuroprotection, and anti-inflammatory effects. In May 2026, donaperminogene seltoplasmid was approved by China's National Medical Products Administration (NMPA) under the brand name Huasuoling (Sedomin) for the treatment of limb ulcers caused by severe lower-limb ischemia (critical limb ischemia) in patients ineligible for revascularization. It is also under clinical evaluation for diabetic peripheral neuropathy, amyotrophic lateral sclerosis (ALS), and coronary artery disease.
- Brand names
- EngensisHuasuolingSedomin
- Other names
- donaperminogene seltoplasmidHGF plasmidrecombinant human hepatocyte growth factor naked plasmid injectionrecombinant human hepatocyte growth factor plasmidseltoplasmidsetoplasmid
02
Targets
HGF (Hepatocyte growth factor)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on donaperminogene seltoplasmid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donaperminogene seltoplasmid.